The log-rank P values were all less than 0.05, suggesting that patients with high expression of PAK1 and HDAC6/10 had higher mortality rates than those with low expression, indicating the potential of PAK1 and HDAC10 as therapeutic targets for breast cancer. This evidence concerns the gene HDAC6 and breast cancer.